BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 11507075)

  • 21. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
    Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
    J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis.
    Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
    J Med Assoc Thai; 2002 May; 85(5):552-9. PubMed ID: 12188384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease.
    Dukers DF; Jaspars LH; Vos W; Oudejans JJ; Hayes D; Cillessen S; Middeldorp JM; Meijer CJ
    J Pathol; 2000 Feb; 190(2):143-9. PubMed ID: 10657011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
    Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
    J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus and Hodgkin's lymphoma.
    Andersson J
    Herpes; 2006 May; 13(1):12-6. PubMed ID: 16732997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Epstein-Barr virus latent membrane protein and Hodgkin's disease in Mexico.
    Quintanilla-Martínez L; Gamboa-Domńquez A; Gamez-Ledesma I; Angeles-Angeles A; Mohar A
    Mod Pathol; 1995 Aug; 8(6):675-9. PubMed ID: 8532705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients.
    Audouin J; Diebold J; Pallesen G
    J Pathol; 1992 Aug; 167(4):381-4. PubMed ID: 1328576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
    Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.
    Delsol G; Meggetto F; Brousset P; Cohen-Knafo E; al Saati T; Rochaix P; Gorguet B; Rubin B; Voigt JJ; Chittal S
    Am J Pathol; 1993 Jun; 142(6):1729-38. PubMed ID: 7685151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High prevalence of the Epstein-Barr virus in a Mexican population with Hodgkin's disease].
    Quintanilla-Martínez L; Gamboa-Domínguez A; Gámez-Ledesma I; Orozco-Estévez H; Angeles-Angeles A
    Rev Invest Clin; 1994; 46(5):355-62. PubMed ID: 7839015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.